Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-02-06T02:44:50.008Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Clinical Trial of Meprobamate in the Management of Difficult and Destructive Female Mental Defectives

Published online by Cambridge University Press:  08 February 2018

W. A. Heaton-Ward  and
J. Jancar
W. A. Heaton-Ward
Affiliation:
Stoke Park Hospital Group, Bristol
J. Jancar
Affiliation:
Stoke Park Hospital, Bristol
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Meprobamate is the shortened name of 2-Methyl-2-n-Propyl-1,3 propanediol dicarbamate, which is also known as Miltown or Equanil.

Type
Original Articles
Information
Journal of Mental Science , Volume 104 , Issue 435 , April 1958 , pp. 454 - 456
Copyright
Copyright © Royal College of Psychiatrists, 1958 

References

1. Pennington, W. M., “The effects of six ataraxics in neuropsychiatric patients”. Read at the Ainerican Psychosomatic Society Meeting, New York City, 6–8 October, 1955.Google Scholar
2. Borrus, J. C., “Study of effect of Miltown on psychiatric states”, J.A.M.A., 1955, 157, 1596.Google Scholar
3. Lemere, M., “New tranquillizing drugs”, Northwest Med., 1955, 54, 1098.Google Scholar
4. Selling, L. S., “Clinical study of a new tranquillizing drug; use of Miltown”, J.A.M.A., 1955, 167, 1594.Google Scholar
5. Perlstein, M. A., “Miltown, its use in convulsive and related disorders”, 1956, J.A.M.A., April.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.